Gcg-XTEN: An Improved Glucagon Capable of Preventing Hypoglycemia without Increasing Baseline Blood Glucose

Nathan C. Geething, Wayne To, Benjamin J. Spink et al. · 2010

Read Gcg-XTEN: An Improved Glucagon Capable of Preventing Hypoglycemia without Increasing Baseline Blood Glucose by Nathan C. Geething, Wayne To, Benjamin J. Spink et al. (2010) in the Tower of Babel, a free online library of public-domain works preserved in clean, searchable text. No sign-up. The full text is served as a plain-text file at a predictable URL, where text is present: https://antarctic-labs.com/tower-of-babel/plos-pone-0010175.txt.

Description

The authors were Nathan Geething, Wayne To, Benjamin Spink, and others. Their 2010 PLOS ONE study improved a rescue hormone for diabetes care. Most diabetes drugs lower blood sugar, but insulin treatment risks driving it too low. Glucagon raises blood sugar and counters that danger, yet it fades fast and can overshoot baseline levels.

The team created Gcg-XTEN, a longer-acting modified glucagon. In their tests it prevented hypoglycemia, dangerously low blood sugar, without raising baseline glucose. A steadier rescue drug could make intensive insulin therapy safer for patients. The work appeared in PLOS ONE in 2010.

Catalog record

CREATORNathan C. Geething, Wayne To, Benjamin J. Spink et al.
YEAR2010
COLLECTIONPAPERS
FORMATTXT
FILE SIZE37 KB
LICENSECreative Commons Attribution License
RIGHTSCC BY
SOURCEPLOS ONE

Source: https://journals.plos.org/plosone/article?id=10.1371/journal.pone.0010175

Browse the full library · About the Tower of Babel